JamesEdwardButrynskiMD

Oncology • Eugene, OR

Instructor in Medicine, Dana-Farber Cancer Institute

Join to view full profile

Are you Dr. Butrynski?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 100 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
520 Country Club Pkwy
Eugene, OR 97401
Phone+1 541-683-5001

Fax+1 541-683-1422
Is this information wrong?

Summary

Dr. James Butrynski, MD is an oncologist in Eugene, Oregon. He is currently licensed to practice medicine in Oregon, Massachusetts, and Washington. He is affiliated with PeaceHealth Sacred Heart Medical Center at RiverBend and is an Instructor in Medicine at Dana-Farber Cancer Institute.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1998 - 1998
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1996 - 1998
Massachusetts General HospitalResidency, Internal Medicine, 1993 - 1996
Wayne State University School of MedicineClass of 1993

Certifications & Licensure

OR State Medical License 2017 - 2025
WA State Medical License 1998 - 2017
MA State Medical License 2007 - 2015
MD State Medical License 1996 - 1998
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer Start of enrollment: 2000 Jul 01
Completed
Phase 2
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2011 May 01
Terminated
Phase 2, Phase 3
Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas Start of enrollment: 2012 Sep 01
Withdrawn
Not Applicable
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors Start of enrollment: 2012 Oct 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

16 citations
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.
Kristin Baird, John Glod, Seth M. Steinberg, Denise K. Reinke, Joseph G. Pressey, Leo Mascarenhas, Noah Federman, Neyssa Marina, Sant P. Chawla, Joanne Lagmay, John M....> ;Sarcoma. 2020 Apr 30
68 citations
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard...
Eytan Ben-Ami, Constance M. Barysauskas, M. von Mehren, Michael Heinrich, Christopher L. Corless, James E. Butrynski, Jeffrey A. Morgan, Andrew J. Wagner, Edwin Choy, ...> ;Annals of Oncology. 2016 Sep 1
26 citations
Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities
A. Alloo, Johanna Sheu, J.E. Butrynski, Daniel J. DeAngelo, S. George, George F. Murphy, Nicole R. LeBoeuf> ;The British Journal of Dermatology. 2015 Aug 1
39 citations
An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
Audrea Szabatura, Frank Cirrone, Christy S Harris, Anne M. McDonnell, Yang Feng, Daniel Voit, Donna Neuberg, James E. Butrynski, David C. Fisher> ;Journal of Oncology Pharmacy Practice. 2015 Jun 1
52 citations
A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial
B. Bui-Nguyen, James E. Butrynski, Nicolas Penel, J.-Y. Blay, N. Isambert, Mohammed M. Milhem, J.M. Kerst, Anna K.L. Reyners, Saskia Litière, Sandrine Marreaud, F. Col...> ;European Journal of Cancer. 2015 Jul 1
48 citations
Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Edwin Choy, Yael Flamand, Sriram Balasubramanian, James E. Butrynski, David C. Harmon, Suzanne George, Gregory M. Cote, Andrew J. Wagner, Jeffrey A. Morgan, Mint Siris...> ;Cancer. 2015 Apr 15
103 citations
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
Edwin Choy, James E. Butrynski, David C. Harmon, Jeffrey A. Morgan, Suzanne George, Andrew J. Wagner, David R. D'Adamo, Gregory M. Cote, Yael Flamand, Cyril H. Benes, ...> ;BMC Cancer. 2014 Nov 5
116 citations
Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
Sant P. Chawla, Lee D. Cranmer, Brian A. Van Tine, Damon R. Reed, Scott H. Okuno, James E. Butrynski, Douglas Adkins, Andrew Eugene Hendifar, Stew Kroll, Kristen N. Ga...> ;Journal of Clinical Oncology. 2014 Oct 10
64 citations
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib
Kristen N. Ganjoo, Victor M. Villalobos, Aya Kamaya, George A. Fisher, James E. Butrynski, Jeffrey A. Morgan, Andrew J. Wagner, David R. D'Adamo, Alex McMillan, George...> ;Annals of Oncology. 2014 Jan 1
62 citations
Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors
Suzanne George, Yang Feng, Judith Manola, Marisa R. Nucci, James E. Butrynski, Jeffrey A. Morgan, Nikhil H. Ramaiya, Richard Quek, Richard T. Penson, Andrew J. Wagner,...> ;Cancer. 2014 Mar 1
60 citations
Cutaneous Radiation-Associated Angiosarcoma of the Breast: Poor Prognosis in a Rare Secondary Malignancy
Elizabeth A. Morgan, David Kozono, Qian Wang, Carlos M. Mery, James E. Butrynski, Elizabeth H. Baldini, Suzanne George, Alessandra F. Nascimento, Chandrajit P. Raut> ;Annals of Surgical Oncology. 2012 Aug 14
58 citations
Extraskeletal osteosarcoma: spectrum of imaging findings.
Grainne Mc Auley, Jyothi P. Jagannathan, Kevin O'Regan, Katherine M. Krajewski, Jason L. Hornick, James E. Butrynski, Nikhil H. Ramaiya> ;AJR. American Journal of Roentgenology. 2012 Nov 23
192 citations
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
Suzanne George, Qian Wang, Michael Heinrich, Christopher L. Corless, Meijun Zhu, James E. Butrynski, Jeffrey A. Morgan, Andrew J. Wagner, Edwin Choy, William D. Tap, J...> ;Journal of Clinical Oncology. 2012 Jul 1
21 citations
Esophageal gastrointestinal stromal tumor: report of 7 patients.
Atul B. Shinagare, Katherine Zukotynski, Katherine M. Krajewski, Jyothi P. Jagannathan, James E. Butrynski, Jason L. Hornick, Nikhil H. Ramaiya> ;Cancer Imaging. 2012 Apr 27
82 citations
Cardiac Angiosarcoma Management and Outcomes: 20-Year Single-institution Experience
Nicole J. Look Hong, Prakash K. Pandalai, Jason L. Hornick, Prem Shekar, David C. Harmon, Yen-Lin Chen, James E. Butrynski, Elizabeth H. Baldini, Chandrajit P. Raut> ;Annals of Surgical Oncology. 2012 Apr 3
85 citations
A to Z of desmoid tumors.
Atul B. Shinagare, Nikhil H. Ramaiya, Jyothi P. Jagannathan, Katherine M. Krajewski, Angela A. Giardino, James E. Butrynski, Chandrajit P. Raut> ;AJR. American Journal of Roentgenology. 2011 Dec 1
77 citations
Clinical presentation and management of mTOR inhibitor-associated stomatitis.
Marcio Augusto de Oliveira, Fabiana Martins, Qian Wang, Stephen T. Sonis, George D. Demetri, Suzanne George, James E. Butrynski, Nathaniel S. Treister> ;Oral Oncology. 2011 Oct 1
8 citations
Imaging of Radiation-Associated Sarcoma
Kevin O'Regan, Matthew N. Hall, J Jagannathan, Angela A. Giardino, Paul J. Kelly, James E. Butrynski, Nikhil H. Ramaiya> ;AJR. American Journal of Roentgenology. 2011 Jul 1
3 citations
PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.
Bruno Vincenzi, Daniele Santini, Gaia Schiavon, Anna Maria Frezza, Marianna Silletta, Pierfilippo Crucitti, Paolo G. Casali, Angelo Paolo Dei Tos, Sabrina Rossi, Sergi...> ;Journal of Cellular Physiology. 2012 Apr 1
65 citations
A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
Kristen N. Ganjoo, Lee D. Cranmer, James E. Butrynski, Daniel A. Rushing, Douglas Adkins, Scott H. Okuno, Gustavo Lorente, Stew Kroll, Virginia K. Langmuir, Sant P. Ch...> ;Oncology. 2011 Jun 1
High rates of histopathologic discordance in sarcoma with implications for clinical care.
Raut CP, George S, Hornick JL, Butrynski JE, Morgan JA, Ready J, Nascimento AF, Fletcher CD, Demetri GD, Baldini EH> ;J. Clin. Oncol.. 2011-05-20
A phase II dose expansion of TH-302 in combination with doxorubicin in soft-tissue sarcoma.
Cranmer LD, Ganjoo KN, Adkins D, Reed DR, Okuno SH, Butrynski JE, Rushing DA, Lorente GA, Kroll S, Chawla SP> ;J. Clin. Oncol.. 2011-05-20
A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).
Trent JC, Wathen K, von Mehren M, Samuels BL, Staddon AP, Choy E, Butrynski JE, Chugh R, Chow WA, Rushing DA, Forscher CA, Baker LH, Schuetze S> ;J. Clin. Oncol.. 2011-05-20
A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).
George S, von Mehren M, Heinrich MC, Wang Q, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Manola J, Yap JT, Van Den Abbeele AD, Solomon S, Fletcher ...> ;J. Clin. Oncol.. 2011-05-20
126 citations
Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
Richard Quek, Qian Wang, Jeffrey A. Morgan, Geoffrey I. Shapiro, James E. Butrynski, Nikhil H. Ramaiya, Tarsha Huftalen, Nicole Jederlinic, Judith Manola, Andrew J. Wa...> ;Clinical Cancer Research. 2011 Feb 15
Join now to see all

Grant Support

Novel Radioimmunotherapy For LymphomaNational Cancer Institute2000–2001

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

PeaceHealth Sacred Heart Medical Center at RiverBendSpringfield, Oregon